Drugs & Targets FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma August 02, 2024Vol.50 No.31
Drugs & Targets FDA approves Shield blood test for colon cancer screening August 02, 2024Vol.50 No.31
Drugs & Targets FDA grants Priority Review to Scemblix for newly-diagnosed Ph+ CML-CP August 02, 2024Vol.50 No.31
Drugs & Targets Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent August 02, 2024Vol.50 No.31
Regulatory News ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications July 26, 2024Vol.50 No.30By Jacquelyn Cobb and Paul Goldberg
Drugs & Targets FDA clears IND for Zymeworks’ antibody drug conjugate ZW191 July 26, 2024Vol.50 No.30
Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.” July 19, 2024Vol.50 No.29By Jacquelyn Cobb
Drugs & Targets FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC July 12, 2024Vol.50 No.28
